Anna Ceribelli

1.6k total citations · 1 hit paper
35 papers, 1.0k citations indexed

About

Anna Ceribelli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Anna Ceribelli has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Anna Ceribelli's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (12 papers) and Cancer Treatment and Pharmacology (6 papers). Anna Ceribelli is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (12 papers) and Cancer Treatment and Pharmacology (6 papers). Anna Ceribelli collaborates with scholars based in Italy, Malaysia and United States. Anna Ceribelli's co-authors include Cesare Gridelli, Alessandro Morabito, Francesco Perrone, Ciro Gallo, Vittorio Gebbia, Adolfo Favaretto, Fortunato Ciardiello, Massimo Di Maïo, Francesco Cognetti and Maria Bassanelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Anna Ceribelli

34 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Ceribelli Italy	15	577	449	159	132	112	35	1.0k
Christelle Clément-Duchêne France	15	379 0.7×	391 0.9×	196 1.2×	73 0.6×	82 0.7×	53	804
José Luís Passos‐Coelho Portugal	21	913 1.6×	288 0.6×	273 1.7×	281 2.1×	80 0.7×	46	1.4k
David Watkins United Kingdom	22	747 1.3×	446 1.0×	322 2.0×	254 1.9×	289 2.6×	81	1.4k
Annette Wigertz Sweden	16	335 0.6×	216 0.5×	197 1.2×	237 1.8×	166 1.5×	19	1.0k
Jesus Vera Aguilera United States	8	845 1.5×	282 0.6×	164 1.0×	101 0.8×	97 0.9×	17	1.3k
C Mettlin United States	17	496 0.9×	459 1.0×	85 0.5×	181 1.4×	153 1.4×	39	1.3k
E. Maartense Netherlands	17	1.3k 2.2×	427 1.0×	150 0.9×	346 2.6×	74 0.7×	49	2.0k
Sandra McDonald United States	15	396 0.7×	755 1.7×	227 1.4×	129 1.0×	216 1.9×	47	1.6k
Lissandra Dal Lago Belgium	18	1.2k 2.0×	254 0.6×	305 1.9×	219 1.7×	124 1.1×	54	1.7k
J. Wendall Goodwin United States	16	522 0.9×	334 0.7×	186 1.2×	102 0.8×	164 1.5×	34	1.0k

Countries citing papers authored by Anna Ceribelli

Since Specialization

Citations

This map shows the geographic impact of Anna Ceribelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Ceribelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Ceribelli more than expected).

Fields of papers citing papers by Anna Ceribelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Ceribelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Ceribelli. The network helps show where Anna Ceribelli may publish in the future.

Co-authorship network of co-authors of Anna Ceribelli

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Ceribelli. A scholar is included among the top collaborators of Anna Ceribelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Ceribelli. Anna Ceribelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bassanelli, Maria, Sara Ramella, Massimo Zeuli, & Anna Ceribelli. (2022). Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC. Anticancer Research. 42(5). 2241–2247. 6 indexed citations

Signorelli, Carlo, Roberta Grande, Salvatore De Marco, et al.. (2021). Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience. Anticancer Research. 41(5). 2553–2561. 1 indexed citations

Ricciuti, Biagio, Carlo Genova, Maria Bassanelli, et al.. (2019). Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer. 20(3). 178–185.e2. 38 indexed citations

Bassanelli, Maria, et al.. (2018). Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. Anticancer Research. 38(7). 3789–3796. 66 indexed citations

Marandino, Ferdinando, Paolo Visca, Enzo Gallo, et al.. (2016). Usefulness of conventional transbronchial needle aspiration in the diagnosis, staging and molecular characterization of pulmonary neoplasias by thin-prep based cytology: experience of a single oncological institute. Journal of Thoracic Disease. 8(8). 2128–2137. 4 indexed citations

Capelletto, Enrica, Simona Carnio, Cesare Gridelli, et al.. (2016). Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non–Small-cell Lung Cancer: A Multicenter Italian Survey. Clinical Lung Cancer. 18(4). 381–387. 6 indexed citations

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

Vari, Sabrina, Sara Pilotto, Marcello Maugeri‐Saccà, et al.. (2013). Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery. 8(11). 1381–1397. 6 indexed citations

Milella, Michèle, Carmen Nuzzo, Emilio Bria, et al.. (2012). EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy. Journal of Thoracic Oncology. 7(4). 672–680. 26 indexed citations

10.

Gridelli, Cesare, Ciro Gallo, Alessandro Morabito, et al.. (2011). Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. Journal of Thoracic Oncology. 7(1). 233–242. 5 indexed citations

11.

Palmieri, Giovannella, Mirella Marino, Carlo Buonerba, et al.. (2011). Imatinib mesylate in thymic epithelial malignancies. Cancer Chemotherapy and Pharmacology. 69(2). 309–315. 40 indexed citations

12.

Marchetti, Antonio, Michèle Milella, Lara Felicioni, et al.. (2009). Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. Neoplasia. 11(10). 1084–1092. 84 indexed citations

13.

Arcangeli, Giorgio, Marcello Benassi, Valentina Pinzi, et al.. (2009). Hypofractionated Conformal Radiotherapy (HCRT) for Primary and Metastatic Lung Cancers with Small Dimension. Strahlentherapie und Onkologie. 185(1). 27–33. 12 indexed citations

14.

Baldi, Alfonso, Marcella Mottolese, Bruno Vincenzi, et al.. (2008). The Serine Protease HtrA1 is a Novel Prognostic Factor for Human Mesothelioma. Pharmacogenomics. 9(8). 1069–1077. 46 indexed citations

15.

Ceribelli, Anna, Maria Simona Pino, & Fabiana Letizia Cecere. (2007). Gender Differences: Implications for Clinical Trials and Practice. Journal of Thoracic Oncology. 2(5). S15–S18. 18 indexed citations

16.

Pino, Maria Simona, Teresa Gamucci, Giovanni Mansueto, et al.. (2007). A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 60(3). 381–386. 5 indexed citations

17.

Gridelli, Cesare, Ciro Gallo, Anna Ceribelli, et al.. (2007). Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. The Lancet Oncology. 8(6). 500–512. 79 indexed citations

18.

Gelibter, Alain, Anna Ceribelli, Michèle Milella, et al.. (2005). Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 131(12). 783–788. 7 indexed citations

19.

Ceribelli, Anna, Cesare Gridelli, Filippo de Marinis, et al.. (2003). Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma. Cancer. 98(2). 337–343. 40 indexed citations

20.

Ceribelli, Anna, et al.. (1994). Weekly gemcitabine in advanced or metastatic solid tumors. Investigational New Drugs. 12(2). 111–119. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact